16D0 Glass, Jon - Thomas Jefferson University - Thomas Jefferson University
Jon Glass, MD

Jon Glass, MD

Contact Dr.  Glass

901 Walnut Street
Suite 400
Philadelphia, PA 19107

(215) 955-7000
(215) 503-9170 fax

Most Recent Peer-reviewed Publications

  1. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma
  2. Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases
  3. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  4. A 60-year-old indian male with altered sensorium and extensive lymphoma of the scalp
  5. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  6. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
  7. Characterization and outcomes of optic nerve gliomas: A population-based analysis
  8. Intravascular lymphoma of the CNS
  9. A phase 1b trial of the combination of the antiangiogenic agent sunitin 0B68 ib and radiation therapy for patients with primary and metastatic central nervous system malignancies
  10. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas
  11. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to l-dopa in the treatment of Parkinson's disease: A randomized, multicenter, open-label, parallel-group study
  12. Central nervous system cancers: Clinical Practice Guidelines in Oncology™
  13. Radiation-induced tumor after stereotactic radiosurgery for an arteriovenous malformation: Case report
  14. Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: Case report
  15. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma
  16. Neurologic Complications of Lymphoma and Leukemia
  17. The Parkinson-control study: A 1-year randomize, double-blind trial comapring piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
  18. Central nervous system cancers Clinical Practice Guidelines in Oncology
  19. Workshop III: Late motor complications of Parkinson's disease
  20. Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme